Tomorrow PTX's Rebecca Lim will be presenting on behalf of the company & shareholders at the annual 'Gene & Cell Conference Asia' in front of the worlds largest pharma, we are talking a number of companies over the $100 billion market cap. It's a big opportunity for our OmniCar platform and networking.
Also, we are expecting at any moment for the PTX-100 expanded cohort to commence. Professor Miles Prince and our CEO Steven were submitting an amendment to the original 1B phase study that would encompass the expanded cohort study activities and were targeting approval/commencement for September.
There are other things in the pipeline like the Peter Mac stealth mode 'Cell enhancement therapy' program that we are expecting some news on but the above two are the obvious key pieces for the month of September.
Cheers.
PTX Price at posting:
27.0¢ Sentiment: Buy Disclosure: Held
